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Involvement of the CLEC3B gene in osteoarthritisDear sir,
In the April 2010 issue of Osteoarthritis and Cartilage Karlsson
and co-workers1 described results from whole genome microarray
analysis and identiﬁed several genes differentially expressed in
osteoarthritis (OA) cartilage compared to normal cartilage.
In this study, the authors report a number of newcandidate genes
not previously associated with OA that display signiﬁcantly higher
expression in OA cartilage than in normal donor cartilage and which
were further veriﬁed using real-time PCR and immunohistochem-
istry. Among the genes that the authors list as not previously associ-
atedwithOA they include the C-type lectindomain family 3,member
B gene (CLEC3B) which is also known as tetranectin (http://www.
ncbi.nlm.nih.gov/gene/7123) with the unofﬁcial symbol TNA.
Overexpression of CLEC3B (TNA) in OA cartilage compared to
normal donors had already been reported2 and an amino acid change
Ser106Gly was found to be associated with genetic susceptibility to
knee OA in a population-based cohort from the UK. This amino acid
change was found to be associated in a case-control study also from
the UK3. Although this gene had previously been implicated in OA,
the results from Karlsson and colleagues lend further support to
a relevant role of this gene in OA, and would suggest that the speciﬁc
involvement of this plasminogen binding protein in the pathogenesis
of OA should be investigated more in depth.
AsKarlsson et al.pointout, theCLEC3Bgenehasbeen implicated in
osteogenesis and bone mineralization4,5. In addition, however, there
is considerable literature on the use of serum and cerebral spine ﬂuid
tetranectin as a biomarker for a number of very different disorders
amongwhichareovariancancer6, Parkinson’sdisease7, andepilepsy8.
Future investigation into the role of CLEC3B/tetranectin in OA should
reveal if tetranectin might also be used as a biomarker for OA.
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